Furazabol

Furazabol
Systematic (IUPAC) name
17-alpha-methyl-5-alpha-androsta-2,3-furazan-17b-ol
Identifiers
CAS number	1239-29-8
ATC code	?
PubChem	14708
Chemical data
Formula	C20H30N2O2
Mol. mass	330.464
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

WikiDoc Resources for Furazabol
Articles
Most recent articles on Furazabol Most cited articles on Furazabol Review articles on Furazabol Articles on Furazabol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Furazabol Images of Furazabol Photos of Furazabol Podcasts & MP3s on Furazabol Videos on Furazabol
Evidence Based Medicine
Cochrane Collaboration on Furazabol Bandolier on Furazabol TRIP on Furazabol
Clinical Trials
Ongoing Trials on Furazabol at Clinical Trials.gov Trial results on Furazabol Clinical Trials on Furazabol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Furazabol NICE Guidance on Furazabol NHS PRODIGY Guidance FDA on Furazabol CDC on Furazabol
Books
Books on Furazabol
News
Furazabol in the news Be alerted to news on Furazabol News trends on Furazabol
Commentary
Blogs on Furazabol
Definitions
Definitions of Furazabol
Patient Resources / Community
Patient resources on Furazabol Discussion groups on Furazabol Patient Handouts on Furazabol Directions to Hospitals Treating Furazabol Risk calculators and risk factors for Furazabol
Healthcare Provider Resources
Symptoms of Furazabol Causes & Risk Factors for Furazabol Diagnostic studies for Furazabol Treatment of Furazabol
Continuing Medical Education (CME)
CME Programs on Furazabol
International
Furazabol en Espanol Furazabol en Francais
Business
Furazabol in the Marketplace Patents on Furazabol
Experimental / Informatics
List of terms related to Furazabol

Furazabol (Miotolan) is a derivative of the anabolic steroid stanozolol. It differs from stanozolol by having a furazan ring system in place of the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally and causes heptatoxicity in some individuals. The more intriguing characteristic of this steroid is that (unlike other anabolic steroids) furazabol has the ability to lower cholesterol levels.

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of Furazabol are a myth. In the 1970s, research studies showed that Furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol. It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that Furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.

Diversion of this obscure pharmaceutical steroid to the black market rarely occurred while it was being manufactured by Daiichi Seiyaku Company in Japan. However, a number of underground labs (UGL) have produced limited quantities of Furazabol in recent years. Additionally, a non-methylated derivative of Furazabol called Furaguno is currently being sold over-the-counter on the sport nutrition market in the United States in 2006 and 2007.